Lidocaine‐derivative JMF2‐1 prevents ovalbumin‐induced airway inflammation by regulating the function and survival of T cells

Abstract

Inhalation of JMF2-1 prevents the cardinal features of asthma by reducing T(H) 2 cytokine generation and lung eosinophilic inflammatory infiltrates via local inhibition of T cell function and survival. JMF2-1 may represent a novel therapeutic alternative for asthma control with distinct advantages over local anaesthetics.